Table 6. Treatment switching and adverse events observed during initial drug treatment of VL.

Initial VL therapy (patients who initially received drug/patients who switched medication)	Second VL drug therapy (patients)	Reason for change in therapy drug (patients)	Adverse events during initial VL therapy (patients)
Pentavalent antimony (12/7)	deoxycholate amphotericin B (6)	toxicity (5); disease severity (1)	renal (1), hepatic (1), and cardiac (1) dysfunction; adverse reactions during infusion (1)
	liposomal amphotericin B (1)	impairment of renal function (1)	renal dysfunction (1)
Deoxycholate amphotericin B (53/24)	pentavalent antimony (1)	outpatient treatment using intramuscular medication (1)	none
	liposomal amphotericin B (23)	toxicity (23)	renal (15), hepatic (3), and muscular (1) dysfunction; adverse reactions during infusion (8); electrolytic abnormalities (10); phlebitis (3)
Liposomal amphotericin B (25/0)	no patient needed to switch VL therapy